Status:
COMPLETED
Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin Infections
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Skin Diseases, Bacterial
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to compare the safety and efficacy of the antibiotic tigecycline with other antibiotics, ampicillin-sulbactam, and amoxicillin-clavulanate in the treatment of a complicate...
Eligibility Criteria
Inclusion
- Clinical diagnosis of complicated skin or skin structure infection
- Male or female, 18 years or older
- Need for intravenous treatment for 4 to 14 days
Exclusion
- Skin infection that can be treated by surgery \& wound care alone
- Diabetic foot ulcers or bedsores where the infection is present longer than 1 week
- Poor circulation such that amputation of the infected site is likely within a month Other exclusions apply
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
550 Patients enrolled
Trial Details
Trial ID
NCT00368537
Start Date
September 1 2006
End Date
September 1 2008
Last Update
August 9 2012
Active Locations (57)
Enter a location and click search to find clinical trials sorted by distance.
1
Scottsdale, Arizona, United States, 85251
2
Jonesboro, Arkansas, United States, 72401
3
Chula Vista, California, United States, 91911
4
Mission Viejo, California, United States, 92691